Caspar da Cunha-Bang

10PUBLICATIONS
46CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cardiology (incl. cardiovascular diseases)Innate immunityHaematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Mar 30, 2026
Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.

Moritz Fürstenau, Carsten Utoft Niemann, Sandra Robrecht

|Jan 28, 2026
Hypertension affects survival and treatment in chronic lymphocytic leukemia.

Noomi Vainer, Christian Brieghel, Klaus Rostgaard

|Aug 27, 2025
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.

Othman Al-Sawaf, Moritz Fürstenau, Adam Giza

|Apr 18, 2025
Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial.

Carsten U Niemann, Julie Dubois, Kazem Nasserinejad

|Mar 01, 2024
It is feasible and safe to stop specialized follow-up of asymptomatic lower-risk chronic lymphocytic leukemia.

Christian Brieghel, Caspar da Cunha-Bang, Jindrich Mourek

|Feb 23, 2024
Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials.

Rebecca Svanberg Teglgaard, Hanne Vibeke Marquart, Hans Jakob Hartling

Pageof 2

Frequent Collaborators

10 joint publications

Carsten Utoft Niemann

6 joint publications

Christian Brieghel

5 joint publications

Arnon P Kater

4 joint publications

Mark-David Levin